secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115533
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028
--------------------------------------------------------------------------------

- Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.
- Net loss $28.5M ($0.20/ADS) vs $2.3M ($0.02) in Q1 2024; R&D up $9.0M to $20.8M.
- Divesiran Phase 2 SANRECO enrollment on track to complete by year-end 2025; EHA presentation June 12-15.
- Cost savings initiatives implemented to extend cash guidance into 2028; Phase 3 readiness for zerlasiran ongoing.
- Appointed Tim McInerney to Board of Directors effective May 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/0001193125-25-115533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/d932196d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer